A meta-analysis of overweight and obese patients with or without diabetes demonstrated that GLP-1R agonists improve plasma lipids and glycemic control and induce weight loss [133], leading to their widespread use in treating type 2 diabetes and obesity [108,134,135,136]. Here, GLP1R is linked to type 2 diabetes mellitus.